ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Mar 15, 2022 13:03 JST
Source:
Eisai
Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen
TOKYO, Mar 15, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer's disease collaboration agreement with Biogen Inc. separately announced today. Effective as of January 1, 2023, Eisai will receive a tiered royalty on net sales of ADUHELM rather than sharing global profits and losses. The details of the royalty rates are shown in the table below.
Economic arrangements for 2022 will remain materially unchanged with Eisai's share of ADUHELM expenses capped at $335 million for the costs related to development, commercialization and manufacturing for the period from January 1, 2022, to December 31, 2022.
In regards to Eisai's financials, no revision will be made at this time to the consolidated earnings forecast for the fiscal year ending March 31, 2022. If Eisai determines that revisions are necessary based on changes including business environment, Eisai will make an announcement as soon as possible.
*ADUHELM is a registered trademark of Biogen Inc.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
Apr 03, 2026 12:33 JST
Hitachi Rail announces agreement to acquire Clever Devices, marking its growth as a global digital mobility player
Apr 03, 2026 11:09 JST
OMRON Healthcare and UCSF launch AFib trial
Apr 03, 2026 00:00 JST
DENSO and FoodVentures Strengthen Collaboration through Capital Partnership in the Agricultural Sector
Apr 02, 2026 19:56 JST
JRC, SKY Perfect JSAT, and Sharp Collaborate to Promote the Ministry of Defense's Publicly Announced Project "Development and Demonstration of Resiliency Technology for Multi-Orbit Communications Systems" Selected for JRC
Apr 02, 2026 16:01 JST
MHIEC Completes Construction of Nanbu Relay Center for Nagasaki Prefecture's Ken'ou-Kennan Clean Authority
Apr 02, 2026 14:57 JST
Moving Beyond the 'Blockbuster' Legacy to Reshape Kidney Disease Treatment Through a Dual-Mechanism Approach: Dialogue with HighTide Therapeutics' CMO Dr. Filip Surmont
Apr 02, 2026 12:00 JST
Mazda EZ-6/Mazda6e Wins 2026 World Car Design of the Year Award
Apr 02, 2026 11:47 JST
Honda Makes Gachaco a Consolidated Subsidiary by Subscribing to New Shares of Gachaco Issued Through Third-party Allotment
Apr 01, 2026 22:09 JST
DENSO Hosted "DENSO DIALOG DAY 2026", Delivers Mid-Term Management Plan "CORE 2030"
Apr 01, 2026 21:54 JST
MHI President Eisaku Ito Offers Words of Encouragement to New Employees at the Company's 2026 Welcoming Ceremony
Apr 01, 2026 13:35 JST
MHI Completes the Transfer Procedures for its Domestic Onshore Wind Power Business
Apr 01, 2026 13:26 JST
Toyota Motor Corporation aims to join Daimler Truck and Volvo Group as equal shareholder in the fuel cell joint venture cellcentric
Mar 31, 2026 23:39 JST
Honda Announces the Establishment of PathAhead Co., Ltd., a Startup Originated from IGNITION, a Honda New Business Creation Program
Mar 31, 2026 21:58 JST
Hitachi Digital Services Strengthens OT-IT Integration with Manufacturing Operations Management Platform
Mar 31, 2026 19:14 JST
Fujitsu and Osaka University of Health and Sport Sciences partner to innovate sports performance with skeleton recognition AI
Mar 31, 2026 17:42 JST
DOCOMO and SK Telecom Publish White Paper on Requirements for Advancing vRAN and AI-RAN in Mobile Networks
Mar 31, 2026 11:00 JST
NEC Supports Ooredoo Algeria in Modernizing Enterprise Network Security with high-performance next-generation firewalls (NGFW)
Mar 31, 2026 10:50 JST
MOL and Hitachi Launch Initiative to Convert Used Ships into Floating Data Centers
Mar 30, 2026 19:21 JST
Resona Holdings, BrainPad, and Fujitsu sign basic agreement for collaboration to transform financial operations with data and AI and advance next-generation data utilization
Mar 30, 2026 15:55 JST
More Latest Release >>
Related Release
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
3/27/2026 8:14:00 PM JST
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
3/27/2026 6:19:00 PM JST
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
3/23/2026 11:19:00 AM JST
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
3/19/2026 10:54:00 AM JST
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
3/17/2026 7:49:00 PM JST
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
3/12/2026 5:21:00 PM JST
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
3/11/2026 12:07:00 PM JST
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
3/2/2026 9:49:00 AM JST
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
2/16/2026 2:03:00 PM JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
2/10/2026 1:34:00 PM JST
More Press release >>